Mandate

Vinge advises Ovako Group in connection with the acquisition of BE Group’s operations in China

June 07, 2013

Vinge has advised Ovako Group in connection with the acquisition of the entire issued share capital in BE (Shanghai) Steel Trading Co., Ltd from BE Group AB (publ). The transaction is subject to approval by the relevant public authorities in China.

Ovako is a leading European producer of engineering steel for customers in the bearing, transport and manufacturing industries. The company has 11 production sites and a number of sales companies in Europe and the USA. Sales in 2012 amounted to EUR 937 million and the company had 3,040 employees. The total production capacity is 1.3 million tonnes of steel per year. The potential acquisition is intended to accelerate Ovako’s plans to establish a service centre in China in order to support Ovako’s customers in Asia by providing specific, niche products.

Vinge’s team advising Ovako Group consisted of partner Henrik Wenckert and associate Nina Farrahi. Partner Qun Gu advised on issues relating to China and Chinese law.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026